Extract
We read with interest the recent study by Suissaet al.[1] published in theEuropean Respiratory Journal. The study used population-based administrative data from the province of Quebec, Canada, to evaluate the association between inhaled corticosteroid (ICS) exposure and lung cancer risk in patients with COPD. The results of the study indicated that ICS use was not associated with lung cancer risk in this patient population.
Abstract
Immortal time bias is common in observational studies; however, in the analysis conducted by Raymakers and colleagues appropriate measures were taken to avoid this biashttp://bit.ly/36042OV
Footnotes
Conflict of interest: A.J.N. Raymakers has nothing to disclose.
Conflict of interest: M. Sadatsafavi reports grants and personal fees from GlaxoSmithKline and AstraZeneca, outside the submitted work.
Conflict of interest: D.D. Sin reports grants from Merck, personal fees for advisory board work from Sanofi-Aventis and Regeneron, grants and personal fees for lectures and advisory board work from Boehringer Ingelheim and AstraZeneca, personal fees for lectures and advisory board work from from Novartis, outside the submitted work.
Conflict of interest: J.M. FitzGerald has nothing to disclose.
Conflict of interest: C.A. Marra has nothing to disclose.
Conflict of interest: L.D. Lynd reports grants from Canadian Institute for Health Research, during the conduct of the study; grants from AstraZeneca, outside the submitted work.
- ReceivedDecember 27, 2019.
- AcceptedJanuary 6, 2020.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
购买访问
CONTACT US
If you have any questions about the ERS publications website, please contactjournals@ersnet.org